fordadistrogene movaparvovec
Gene therapyexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jan 23, 2018 (NCT03362502)
Timeline
Indications
Studied for
Mechanism of action
- Dystrophin pre-mRNASupplementation
Dystrophin pre-mRNA supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594336 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05689164 | Phase 3 | Mar 13, 2023 | Pfizer |
| NCT05429372 | Phase 2 | Aug 8, 2022 | Pfizer |
| NCT04281485 | Phase 3 | May 13, 2020 | Pfizer |
| NCT03362502 | Phase 1 | Jan 23, 2018 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 3 | 2018 |
1 organizations
Page 1 / 1